-

2022 Bladder Cancer Update Bulletin: Key Opinion Leader (KOL) Views on Recent Developments - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Bladder Cancer: Update Bulletin #2" newsletter has been added to ResearchAndMarkets.com's offering.

This edition presents leading key opinion leader (KOL) views on recent developments in the Bladder Cancer market.

Topics covered include: Bristol-Myers Squibb (BMS) presenting positive data from a Phase I/II study investigating a combination of its PD-1 inhibitor Opdivo (nivolumab) with its pipeline indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, BMS-986205, in heavily pretreated patients with advanced bladder cancer; BioCanCell announcing final results for its Phase IIb combination trial investigating its lead compound BC-819 in combination with the BCG vaccine in 38 patients with intermediate-and high-risk non-muscle invasive bladder cancer (NMIBC); KOLs offering their updated opinions on the the supply status of the BCG vaccine in the US and key European markets.

Business Questions:

  • How do the KOLs perceive the Phase II combination results for BMS' Opdivo with the IDO inhibitor BMS-986205 in patients with advanced bladder cancer?
  • Do KOLs view PD-1/PD-L1 and IDO inhibition as a viable combination approach going forward?
  • What are experts' thoughts on PD-L1 expression and its future use as a biomarker in patients with bladder cancer?
  • Do KOLs hold any other concerns about dual immunotherapy combinations such as cost, access or increased risk of toxicity?
  • If approved, how and when would KOLs consider using the combination approach of Opdivo with an IDO inhibitor?
  • Based on published Phase II data, how do the experts view the results so far for BC-819 with BCG in patients with NMIBC?
  • Are the KOLs enthusiastic about intravesical gene therapies as treatments for NMIBC and if so, why?
  • How do the experts perceive the planned Phase III trial investigating BC-819 in patients that are BCG-recurrent?
  • If approved, can BC-819 gain market share in patients with high-risk or intermediate-risk NMIBC?
  • What are KOLs' opinions on the supply shortages previously reported for the BCG vaccine and are they being addressed?

For more information about this newsletter visit https://www.researchandmarkets.com/r/9ke1kl

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Industry:

Research and Markets

Release Versions
English

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

More News From Research and Markets

Quantum Cryptography Market to 2035: Opportunities by Type of Offering, Type of Security, Type of Service, Type of Component, Type of Deployment Protocol, Type of Industry, Company Size, and Region - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Quantum Cryptography Market Till 2035: Distribution by Type of Offering, Type of Security, Type of Service, Type of Component, Type of Deployment Protocol, Type of Industry, Company Size, and Key Geographical Regions: Industry Trends and Global Forecasts" has been added to ResearchAndMarkets.com's offering. The global quantum cryptography market is set to expand from USD 0.92 billion this year to an impressive USD 16.13 billion by 2035, reflecting a CAGR of 29.72%...

DevOps Market Trends and Investment Opportunities to 2035: Companies Recognize Value in Rapidly Improving Software Delivery and Operational Effectiveness - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "DevOps Market Till 2035: Distribution by Type of Offering, Type of Deployment Model, Type of Tools, Type of Industry Vertical, Company Size, and Key Geographical Regions: Industry Trends and Global Forecasts" has been added to ResearchAndMarkets.com's offering. The global DevOps market, valued at USD 13.29 billion this year, is projected to soar to USD 108.26 billion by 2035, growing at a Compound Annual Growth Rate (CAGR) of 21.01% over the forecast period. This s...

Hydrogen Storage Tanks and Transportation Market Report 2026-2036: Analysis of Lucrative Areas for Targeted Investments - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Hydrogen Storage Tanks and Transportation Market Report 2026-2036" has been added to ResearchAndMarkets.com's offering. Overall world revenue for the Hydrogen Storage Tanks and Transportation Market is anticipated to surpass US$1.57 billion by 2026, according to current calculations, with strong revenue growth projected through to 2036. The report identifies key organizations and analyzes their capabilities, progress, and commercial prospects to help industry playe...
Back to Newsroom